Study Claim: Sternal hydrolysed collagen type II with hyaluronic acid, derived from BioCell Collagen II, is safe and effective in relieving pain and stiffness from osteoarthritis.
Published: Kalman, DS, et al. A randomised double-blind clinical pilot trial evaluating the safety and efficacy of hydrolysed collagen type II in adults with osteoarthritis. FASEB J 2004; A90.
Abstract: In a randomised, double-blind, placebo-controlled clinical trial, 16 subjects with osteoarthritis of the knee or hand were enrolled for a two-month intervention study. Subjects were balanced at baseline for age, race, gender and osteoarthritis location. Subjects who were on a COX-2 inhibitor or NSAID therapy were allowed to continue therapy. Those who were taking or recently took dietary supplements for joint health were excluded, as were subjects who had clinically significant medical conditions.
Subjects were randomised to receive 1,000mg of a hydrolysed type II collagen product, avian source (HC2) or placebo. The specific aims were to compare the two with respect to perceived pain, mobility/stiffness, activities of daily living profile and physical activity levels (by WOMAC scores), overall quality of life, and overall quality of sleep.
The group receiving HC2 experienced a significant improvement in all WOMAC subscales and in its total WOMAC score compared to placebo. Adverse events were not different between the groups and were neither significant nor considered related to the test product or placebo. Compliance was about 94 per cent. In this limited sample size, HC2 appeared to be a safe and effective dietary supplement for the adjunctive treatment of osteoarthritis.
Potential applications: BioCell Technology?s BioCell Collagen II, for use as a dietary supplement, is a natural hydrolyzed type II collagen ingredient that provides a complex matrix of elements (collagen type II, chondroitin sulfate and hyaluronic acid) for the support of joint health.
+1 714 632 1231
Study Claim: Isolated soy protein consumption improves several markers that may be beneficial for type 2 diabetic patients with nephropathy.
Published: Teixeira SR, et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr 2004 Aug; 134(8):1874-80.
Abstract: Soy protein has been shown to exhibit several beneficial effects on renal function in nondiabetic patients with nephropathy and to improve serum lipids. This study examined the effects of isolated soy protein consumption on urinary albumin excretion, serum lipids, plasma amino acids and isoflavones in diabetic patients with nephropathy.
A total of 14 male patients with type 2 diabetes and nephropathy were followed in a crossover design for seven months. The study comprised two eight-week intervention periods, placed between a four-week lead-in and two four-week washout periods. In the two intervention periods, 0.5g/kg body weight per day of the dietary protein was provided as either isolated soy protein (ISP) or casein, in random order. Blood and urine samples were collected at the beginning and end of each period. Data were analysed by multiple linear regression for a repeated-measure design.
Isolated soy protein consumption led to changes of -9.5% in urinary albumin excretion (a marker for kidney damage), -0.45% in the total-to-HDL-cholesterol ratio, -0.20% in the LDL-to-HDL cholesterol ratio, and +4.3% in HDL cholesterol. Plasma arginine concentrations, the arginine-to-lysine ratio, and plasma isoflavone concentrations were higher after ISP consumption. Urinary albumin excretion was negatively correlated with plasma total isoflavones, daidzein and O-desmethylangolesin.
Potential applications: The Solae Company?s soy products are available in flours, concentrates and isolates, and may be beneficial to overweight people following a low-carb diet high in protein.
+1 314 982 2588